Abstract
Most vaccines are designed as a prophylactic measure, that is, to stimulate the immune response so that on subsequent exposure of the vaccinated individual to the infectious agent involved, the extent of infection is so low that disease does not occur. There is also increasing interest in designing vaccines that may be effective as a therapeutic measure.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ada GL (1990) The immune response to antigens: the immunological principles of vaccination. Lancet 335:523–526
Ada GL (1993) Vaccines. In: Paul WE (ed) Fundamental immunology, 3rd edn. Raven, New York, pp 1309–1352
Ada GL (1994) Twenty years into the saga of MHC restriction. Immunol Cell Biol 72:447–454
Afonso LCC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P (1994) The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235–237
Cadoz M, Strady A, Meigner B, Taylor J, Tartaglia J, Paoletti E, Plotkin S (1992) Immunization with canarypox virus expressing rabies glycoprotein. Lancet 339:1429–1432
Cooper PD (1994) The selective induction of different immune responses by vaccine adjuvants. In: Ada GL (ed) Strategies in vaccine design. Landes, Austin, pp 129–158
Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC (1992) Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938–1940
Fenner F (1984) Viral vectors for vaccines. In: Bell R, Torrigiani G (eds) New approaches for vaccine development. Schwabe, Basel, pp 187–192
Gautam AM, Glynn P (1990) Competition between foreign and self proteins in antigen presentation. Ovalbumin can inhibit activation of myelin basic protein-specific T-cells. J Immunol 144:1177–1180
Geisow MJ (1991) Unravelling the mysteries of molecular audit: MHC class I restriction. Tibtech 9:403–40
Griffin DE, Levine B, Tyor WB, Irani DN (1992) The immune response in viral encephalitis. Semin Immunol 4:111–119
Halsey NA (1993) Increased mortality following high titer measles vaccines: too much of a good thing. Pediatr Infect Dis 12:462–465
Jackson DC, Ada GL, Tha Lha R (1976) Cytotoxic T cells recognize very early, minor changes in ectromelia virus-infected target cells. Aust J Exp Biol Med Sei 54:349–363
Kapikian AZ, Mitchell RH, Chanock RM (1969) An epidemiological study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with inactivated RS virus vaccine. Am J Epidemiol 89:405–421
Kaumaya PTP, Berndt KD, Heidorn DB, Trewhella J, Kezdy FJ, Goldberg E (1990) Synthesis and biochemical characterization of engineered topographic immunogenic determinants with topology. Biochemistry 29:13–23
Larson HS, Russell RG, Rouse BY (1983) Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytes. Infect Immunol 41:197–204
Leung KN, Ada GL (1982) Different functions of subsets of effector T-cells in murine influenza virus infection. Cell Immunol 67:312–324
Levine MM (1994) Typhoid fever vaccines. In: Plotkin SA, Mortimer EA (eds) Vaccines, 2nd edn. Saunders, Philadelphia, pp 597–634
Maassab HF, Shaw MW, Heilman CA (1994) Live influenza virus vaccine. In: Plotkin SA, Mortimer EA (eds) Vaccines, 2nd edn. Saunders, Philadelphia, pp 781–801
Mortimer EA (1994) Pertussis vaccine. In: Plotkin SA, Mortimer EA (eds) Vaccines, 2nd edn. Saunders, Philadelphia, pp 91–136
Pruksakorn S, Currie B, Brandt E, Martin D, Galbraith A, Phornphutkul C, Hunsakunachai S, Manmontri A, Good MF (1994) Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci. Lancet 344:639–642
Ramsay AJ, Husband AJ, Ramshaw IA, Bao S, Mattaei KI, Koehler G, Kopf M (1994) The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264:561–563
Ramshaw I, Ruby J, Ramsay A, Ada G, Karupiah G (1992) Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo. Immunol Rev 127:157–182
Sharma DP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA (1996) Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lym- phocyte responses and exacerbates vaccinia virus infection in vivo. J Virol 70:7103–7107
Tartaglia J, Perkus ME, Taylor J (1992) NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217–232
Taylor G (1994) The role of antibody in controlling and/or clearing virus infections. In: Ada GL (ed) Strategies in vaccine design. Landes, Austin, pp 17–34
Zinkernagel RM, Althage A (1977) Anti-viral protection by virus-immune cytotoxic T cells: infected target T-cells are lysed before infectious virus progeny is assembled. J Exp Med 145:644–651
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Dorner, F., Barrett, P.N. (1998). Vaccine Technologies: Looking to the Future. In: Eibl, M.M., Huber, C., Peter, H.H., Wahn, U. (eds) Symposium in Immunology VII. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80466-3_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-80466-3_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-63360-0
Online ISBN: 978-3-642-80466-3
eBook Packages: Springer Book Archive